Hemodynamic data in sham-operated and MI rats
| HR | MAP | LVEDP | dP/dtmax | |
|---|---|---|---|---|
| bpm | mm Hg | mm Hg | mm Hg/s | |
| Sham | 361 ± 5.6 | 111 ± 2.1 | 10.2 ± 1.1 | 8.6 ± 0.5 |
| Placebo-MI | 373 ± 6.2 | 82 ± 2.02-a | 21.1 ± 2.32-a | 4.9 ± 0.52-a |
| Mibefradil-MI | 369 ± 5.4 | 102 ± 2.42-b | 14.1 ± 2.72-c 2-b | 7.1 ± 0.42-c 2-b |
| Verapamil-MI | 343 ± 4.6 | 81 ± 2.22-a | 20.0 ± 2.82-a 2-d | 5.3 ± 0.62-a 2-e |
| Amlodipine-MI | 372 ± 5.1 | 96 ± 2.32-e 2-f | 18.1 ± 2.42-a 2-e | 5.9 ± 0.52-a 2-e |
Values are means ± S.E.
sham, sham-operated rats; placebo-MI, infarcted rats at 6 weeks post-MI with placebo treatment; mibefradil-MI, infarcted rats at 6 weeks post-MI with mibefradil treatment; verapamil-MI, infarcted rats at 6 weeks post-MI with verapamil treatment; amlodipine-MI, infarcted rats at 6 weeks post-MI with amlodipine treatment (n = 6 in each group).
↵2-a p < .01 versus sham group.
↵2-b p < .01 versus placebo-MI group.
↵2-c p < .05.
↵2-d p < .01 versus mibefradil-MI group.
↵2-e p < .05.
↵2-f p < .05.